Michael R Shurin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5540111/publications.pdf

Version: 2024-02-01

160 papers	7,461 citations	44069 48 h-index	62596 80 g-index
167 all docs	167 docs citations	167 times ranked	10182 citing authors

#	Article	IF	Citations
1	OUP accepted manuscript. journal of applied laboratory medicine, The, 2022, , .	1.3	0
2	COVID-19 mRNA Vaccines May Cause False Reactivity in Some Serologic Laboratory Tests, Including Rapid Plasma Reagin Tests. American Journal of Clinical Pathology, 2022, 158, 162-166.	0.7	4
3	A Carbon Nanotube Sensor Array for the Label-Free Discrimination of Live and Dead Cells with Machine Learning. Analytical Chemistry, 2022, 94, 3565-3573.	6.5	9
4	Nitrogen-Doped Carbon Nanotube Cups for Cancer Therapy. ACS Applied Nano Materials, 2022, 5, 13685-13696.	5.0	4
5	Cerebrospinal Fluid Leak Detection with a Carbon Nanotube-Based Field-Effect Transistor Biosensing Platform. ACS Applied Materials & Interfaces, 2022, 14, 1684-1691.	8.0	7
6	Tumor Innervation: History, Methodologies, and Significance. Cancers, 2022, 14, 1979.	3.7	8
7	Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy. Journal of Clinical Investigation, 2022, 132, .	8.2	33
8	Regulation of Carcinogenesis by Sensory Neurons and Neuromediators. Cancers, 2022, 14, 2333.	3.7	12
9	Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses. Cancer Immunology Research, 2022, 10, 1141-1154.	3.4	13
10	Variable Performance in 6 Commercial SARS-CoV-2 Antibody Assays May Affect Convalescent Plasma and Seroprevalence Screening. American Journal of Clinical Pathology, 2021, 155, 343-353.	0.7	27
11	Notch signaling defects in NK cells in patients with cancer. Cancer Immunology, Immunotherapy, 2021, 70, 981-988.	4.2	4
12	Rapid Detection of SARS-CoV-2 Antigens Using High-Purity Semiconducting Single-Walled Carbon Nanotube-Based Field-Effect Transistors. ACS Applied Materials & Interfaces, 2021, 13, 10321-10327.	8.0	139
13	Neuroimmune Regulation of Surgery-Associated Metastases. Cells, 2021, 10, 454.	4.1	7
14	A Cross-Sectional Study of SARS-CoV-2 Seroprevalence between Fall 2020 and February 2021 in Allegheny County, Western Pennsylvania, USA. Pathogens, 2021, 10, 710.	2.8	8
15	Antibody Responses After mRNA-Based COVID-19 Vaccination in Residential Older Adults: Implications for Reopening. Journal of the American Medical Directors Association, 2021, 22, 1593-1598.	2.5	25
16	Multiplex assessment of SARS-CoV-2 antibodies improves assay sensitivity and correlation with neutralizing antibodies. Clinical Biochemistry, 2021, 97, 54-61.	1.9	8
17	Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiology Spectrum, 2021, 9, e0034121.	3.0	114
18	SARS-CoV-2 Serologic Immune Response in Exogenously Immunosuppressed Patients. journal of applied laboratory medicine, The, 2021, 6, 486-490.	1.3	17

#	Article	IF	Citations
19	Immunomodulation by Schwann cells in disease. Cancer Immunology, Immunotherapy, 2020, 69, 245-253.	4.2	32
20	A novel approach to remove interference of therapeutic monoclonal antibody with serum protein electrophoresis. Clinical Biochemistry, 2020, 75, 40-47.	1.9	8
21	The Neuroimmune Axis in the Tumor Microenvironment. Journal of Immunology, 2020, 204, 280-285.	0.8	39
22	Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring. journal of applied laboratory medicine, The, 2020, 5, 29-40.	1.3	10
23	Racial Differences in S100b Levels in Persons with Schizophrenia. Psychiatric Quarterly, 2020, 91, 137-145.	2.1	8
24	Dysregulated NF-ÎºBâ€“Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunology Research, 2020, 8, 1554-1567.	3.4	15
25	Pediatric Hypereosinophilia, Liver Disfunction, and Hemolytic Anemia with Autoimmune Differential. journal of applied laboratory medicine, The, 2020, 5, 1111-1116.	1.3	0
26	Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients. Clinical Biochemistry, 2020, 86, 8-14.	1.9	9
27	Assessing Immune Response to SARS-CoV-2 Infection . ImmunoTargets and Therapy, 2020, Volume 9, 111-114.	5.8	10
28	New Syphilis Serology Testing Requires New Reporting Algorithms. journal of applied laboratory medicine, The, 2020, 5, 601-604.	1.3	0
29	Melanoma-Induced Reprogramming of Schwann Cell Signaling Aids Tumor Growth. Cancer Research, 2019, 79, 2736-2747.	0.9	48
30	Abnormal Expression of c-Myc Oncogene in NK Cells in Patients with Cancer. International Journal of Molecular Sciences, 2019, 20, 756.	4.1	14
31	Schwann cells shape the neuro-immune environs and control cancer progression. Cancer Immunology, Immunotherapy, 2019, 68, 1819-1829.	4.2	37
32	Blocking IL-1Î² reverses the immunosuppression in mouse breast cancer and synergizes with antiâ€“PD-1 for tumor abrogation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1361-1369.	7.1	302
33	Fibrous nanocellulose, crystalline nanocellulose, carbon nanotubes, and crocidolite asbestos elicit disparate immune responses upon pharyngeal aspiration in mice. Journal of Immunotoxicology, 2018, 15, 12-23.	1.7	45
34	Characterization of pulmonary responses in mice to asbestos/asbestiform fibers using gene expression profiles. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2018, 81, 60-79.	2.3	11
35	Oncogenes in immune cells as potential therapeutic targets. ImmunoTargets and Therapy, 2018, Volume 7, 21-28.	5.8	11
36	Immunological targets for cancer therapy: new recognition. ImmunoTargets and Therapy, 2018, Volume 7, 83-85.	5.8	13

#	Article	IF	Citations
37	Targeting myeloid regulators by paclitaxel-loaded enzymatically degradable nanocups. Nanoscale, 2018, 10, 17990-18000.	5.6	20
38	Schwann Cells Augment Cell Spreading and Metastasis of Lung Cancer. Cancer Research, 2018, 78, 5927-5939.	0.9	54
39	Osteopontin controls immunosuppression in the tumor microenvironment. Journal of Clinical Investigation, 2018, 128, 5209-5212.	8.2	38
40	Respiratory System, Part Two: Allergy and Asthma. , 2017, , 243-253.		3
41	Ins and Outs in Environmental and Occupational Safety Studies of Asthma and Engineered Nanomaterials. ACS Nano, 2017, 11, 7565-7571.	14.6	14
42	Alterations of oncogenes expression in NK cells in patients with cancer. Immunity, Inflammation and Disease, 2017, 5, 493-502.	2.7	11
43	Nanoelectronic Discrimination of Nonmalignant and Malignant Cells Using Nanotube Field-Effect Transistors. ACS Sensors, 2017, 2, 1128-1132.	7.8	20
44	Mediation of the single-walled carbon nanotubes induced pulmonary fibrogenic response by osteopontin and TGF-Î²1. Experimental Lung Research, 2017, 43, 311-326.	1.2	19
45	Schwann cells: a new player in the tumor microenvironment. Cancer Immunology, Immunotherapy, 2017, 66, 959-968.	4.2	39
46	Targeting Myeloid-Derived Suppressor Cells in Cancer. Advances in Experimental Medicine and Biology, 2017, 1036, 105-128.	1.6	49
47	Dendritic Cells in the Tumor Microenvironment. , 2016, , 499-511.		1
48	Impact of the Sensory Neurons on Melanoma Growth In Vivo. PLoS ONE, 2016, 11, e0156095.	2.5	29
49	BAFF and APRIL from Activin Aâ€“Treated Dendritic Cells Upregulate the Antitumor Efficacy of Dendritic Cells In Vivo. Cancer Research, 2016, 76, 4959-4969.	0.9	20
50	Tumor-derived factors modulating dendritic cell function. Cancer Immunology, Immunotherapy, 2016, 65, 821-833.	4.2	107
51	Enzymatic oxidative biodegradation of nanoparticles: Mechanisms, significance and applications. Toxicology and Applied Pharmacology, 2016, 299, 58-69.	2.8	89
52	Current understanding of interactions between nanoparticles and the immune system. Toxicology and Applied Pharmacology, 2016, 299, 78-89.	2.8	236
53	Nano-Gold Corking and Enzymatic Uncorking of Carbon Nanotube Cups. Journal of the American Chemical Society, 2015, 137, 675-684.	13.7	36
54	Resolving Transferrin Isoforms via Agarose Gel Electrophoresis. Laboratory Medicine, 2015, 46, 26-33.	1.2	3

#	Article	IF	Citations
55	Payload drug vs. nanocarrier biodegradation by myeloperoxidase- and peroxynitrite-mediated oxidations: pharmacokinetic implications. Nanoscale, 2015, 7, 8689-8694.	5.6	15
56	MDSC and TGFÎ² Are Required for Facilitation of Tumor Growth in the Lungs of Mice Exposed to Carbon Nanotubes. Cancer Research, 2015, 75, 1615-1623.	0.9	50
57	Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy. Cancer Microenvironment, 2015, 8, 57-64.	3.1	21
58	Abnormalities in the male reproductive system after exposure to diesel and biodiesel blend. Environmental and Molecular Mutagenesis, 2015, 56, 265-276.	2.2	18
59	Myeloid regulatory cells in tumor spreading and metastasis. Immunobiology, 2015, 220, 236-242.	1.9	105
60	Comorbid Development of Infection and Cancer. , 2015, , 315-332.		0
61	Infection and Cancer: Multi-directorial Relationship. , 2015, , 1-10.		1
62	Origin and pharmacological modulation of tumorâ€associated regulatory dendritic cells. International Journal of Cancer, 2014, 134, 2633-2645.	5.1	47
63	Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunology, Immunotherapy, 2014, 63, 45-57.	4.2	56
64	Graphene Oxide Attenuates Th2-Type Immune Responses, but Augments Airway Remodeling and Hyperresponsiveness in a Murine Model of Asthma. ACS Nano, 2014, 8, 5585-5599.	14.6	51
65	C-reactive protein and lung diseases. International Journal of Biochemistry and Cell Biology, 2014, 53, 77-88.	2.8	69
66	Immunobiology of Dendritic Cells in Cancer. , 2014, , 151-184.		2
67	Immunosuppressive Mechanisms of Regulatory Dendritic Cells in Cancer. Cancer Microenvironment, 2013, 6, 159-167.	3.1	90
68	Dual role of immunomodulation by anticancer chemotherapy. Nature Medicine, 2013, 19, 20-22.	30.7	37
69	Biodiesel versus diesel exposure: Enhanced pulmonary inflammation, oxidative stress, and differential morphological changes in the mouse lung. Toxicology and Applied Pharmacology, 2013, 272, 373-383.	2.8	50
70	Carbon Nanotubes Enhance Metastatic Growth of Lung Carcinoma via Upâ€Regulation of Myeloidâ€Derived Suppressor Cells. Small, 2013, 9, 1691-1695.	10.0	61
71	Graphene Oxide, But Not Fullerenes, Targets Immunoproteasomes and Suppresses Antigen Presentation by Dendritic Cells. Small, 2013, 9, 1686-1690.	10.0	75
72	Dual Acute Proinflammatory and Antifibrotic Pulmonary Effects of Short Palate, Lung, and Nasal Epithelium Cloneâ€“1 after Exposure to Carbon Nanotubes. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 759-767.	2.9	31

#	Article	IF	Citations
73	Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model. Journal of Immunology, 2013, 190, 2464-2471.	0.8	195
74	The Role of TLR4 in the Paclitaxel Effects on Neuronal Growth In Vitro. PLoS ONE, 2013, 8, e56886.	2.5	20
75	Dendritic Cells in the Cancer Microenvironment. Journal of Cancer, 2013, 4, 36-44.	2.5	289
76	Role of the Immunological Environment in Cancer Initiation, Development and Progression. , 2013, , 1-12.		1
77	ChemoImmunoModulation: Focus on Myeloid Regulatory Cells. , 2013, , 603-619.		0
78	Analysis of Myeloid-Derived Suppressor Cells in Patients with Cancer. , 2013, , 707-723.		0
79	Evaluation of the Tumor Immunoenvironment in Clinical Trials. , 2013, , 695-706.		1
80	ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents. Current Medicinal Chemistry, 2012, 19, 1792-1803.	2.4	74
81	Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. Journal of Immunotoxicology, 2012, 9, 275-281.	1.7	52
82	Cancer and infection: friends or foes?. Future Oncology, 2012, 8, 1061-1064.	2.4	2
83	Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cellsin vitroin a TLR4-independent manner. Journal of Immunotoxicology, 2012, 9, 292-300.	1.7	124
84	Conference overview: Cancer Immunotherapy and Immunomonitoring (CITIM): Moving forward. Journal of Immunotoxicology, 2012, 9, 231-235.	1.7	2
85	ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials. Cells, 2012, 1, 111-126.	4.1	52
86	Cancer as an immune-mediated disease. ImmunoTargets and Therapy, 2012, 1, 1.	5.8	35
87	Tumor associated regulatory dendritic cells. Seminars in Cancer Biology, 2012, 22, 298-306.	9.6	112
88	Regulatory dendritic cells in the tumor immunoenvironment. Cancer Immunology, Immunotherapy, 2012, 61, 223-230.	4.2	50
89	Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunology, Immunotherapy, 2012, 61, 239-247.	4.2	24
90	Direct Effects of Carbon Nanotubes on Dendritic Cells Induce Immune Suppression Upon Pulmonary Exposure. ACS Nano, 2011, 5, 5755-5762.	14.6	116

#	Article	IF	Citations
91	Regulatory dendritic cells: New targets for cancer immunotherapy. Cancer Biology and Therapy, 2011, 11, 988-992.	3.4	54
92	Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cellular Oncology (Dordrecht), 2011, 34, 97-106.	4.4	78
93	Targeting myeloid regulatory cells in cancer by chemotherapeutic agents. Immunologic Research, 2011, 50, 276-285.	2.9	36
94	Conference Scene: Immunotherapy reaches new milestones in cancer eradication. Immunotherapy, 2011, 3, 1131-1137.	2.0	2
95	Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?. Expert Opinion on Biological Therapy, 2010, 10, 1539-1553.	3.1	19
96	MicroRNAs are invading the tumor microenvironment: Fibroblast microRNAs regulate tumor cell motility and invasiveness. Cell Cycle, 2010, 9, 4430-4430.	2.6	2
97	Epigenetic Mechanisms of Promigratory Chemokine CXCL14 Regulation in Human Prostate Cancer Cells. Cancer Research, 2010, 70, 4394-4401.	0.9	48
98	New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Review of Vaccines, 2010, 9, 601-616.	4.4	142
99	Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism. Journal of Immunology, 2009, 183, 137-144.	0.8	221
100	New perspectives in cancer immunotherapy and immunomonitoring. Future Oncology, 2009, 5, 941-944.	2.4	5
101	Recognition of Live Phosphatidylserine-Labeled Tumor Cells by Dendritic Cells: A Novel Approach to Immunotherapy of Skin Cancer. Cancer Research, 2009, 69, 2487-2496.	0.9	12
102	Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells. Cancer Immunology, Immunotherapy, 2009, 58, 567-574.	4.2	22
103	Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. Journal of Translational Medicine, 2009, 7, 58.	4.4	128
104	Cancer Therapy and Dendritic Cell Immunomodulation. , 2009, , 201-216.		5
105	Dendritic Cells in Cancer: Emergenceof the Discipline. , 2009, , 11-30.		1
106	Dopamine receptors in human lymphocytes: Radioligand binding and quantitative RT-PCR assays. Journal of Neuroscience Methods, 2008, 174, 272-280.	2.5	49
107	Immunobiology of Dendritic Cells in Cancer. , 2008, , 101-130.		2
108	Low-dose Chemotherapeutic Agents Regulate Small Rho GTPase Activity in Dendritic Cells. Journal of Immunotherapy, 2008, 31, 491-499.	2.4	36

#	Article	IF	Citations
109	Cyanidin-3-rutinoside, a Natural Polyphenol Antioxidant, Selectively Kills Leukemic Cells by Induction of Oxidative Stress. Journal of Biological Chemistry, 2007, 282, 13468-13476.	3.4	185
110	Small Rho GTPases Mediate Tumor-Induced Inhibition of Endocytic Activity of Dendritic Cells. Journal of Immunology, 2007, 178, 7787-7793.	0.8	30
111	Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth. Clinical Cancer Research, 2007, 13, 5455-5462.	7.0	120
112	Dynamic alteration of soluble serum biomarkers in healthy aging. Cytokine, 2007, 39, 123-129.	3.2	91
113	Optimizing dendritic cell-based immunotherapy for cancer. Expert Review of Vaccines, 2007, 6, 333-345.	4.4	29
114	Aging and the dendritic cell system: Implications for cancer. Critical Reviews in Oncology/Hematology, 2007, 64, 90-105.	4.4	69
115	Immune-Mediated Diseases: Where Do We Stand?. Advances in Experimental Medicine and Biology, 2007, , 1-12.	1.6	13
116	Inhibition of Dendritic Cell Generation and Function by Serum from Prostate Cancer Patients: Correlation with Serum-Free PSA. Advances in Experimental Medicine and Biology, 2007, 601, 173-182.	1.6	18
117	Differences in Dendritic Cell Activation and Distribution After Intravenous, Intraperitoneal, and Subcutaneous Injection of Lymphoma Cells in Mice. Advances in Experimental Medicine and Biology, 2007, 601, 257-264.	1.6	2
118	Immune-mediated diseases: where do we stand?. Advances in Experimental Medicine and Biology, 2007, 601, 3-12.	1.6	14
119	Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?. Cancer and Metastasis Reviews, 2006, 25, 333-356.	5.9	163
120	Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBLin vivo following intratumoral administration of viral vectors or transduced dendritic cells. Journal of Gene Medicine, 2006, 8, 129-137.	2.8	24
121	Restoration by IL-15 of MHC Class I Antigen-Processing Machinery in Human Dendritic Cells Inhibited by Tumor-Derived Gangliosides. Journal of Immunology, 2005, 175, 3045-3052.	0.8	71
122	Handling Sera and Obtaining Fluid from Different Compartments: Practical Considerations. , 2005, , 121-130.		0
123	Loss of New Chemokine CXCL14 in Tumor Tissue Is Associated with Low Infiltration by Dendritic Cells (DC), while Restoration of Human CXCL14 Expression in Tumor Cells Causes Attraction of DC Both In Vitro and In Vivo. Journal of Immunology, 2005, 174, 5490-5498.	0.8	198
124	Small Rho GTPases Regulate Antigen Presentation in Dendritic Cells. Journal of Immunology, 2005, 174, 3394-3400.	0.8	67
125	Immunoglobulin Titers and Immunoglobulin Subtypes. , 2005, , 158-171.		1
126	Antigen-Processing Machinery in Human Dendritic Cells: Up-Regulation by Maturation and Down-Regulation by Tumor Cells. Journal of Immunology, 2004, 173, 1526-1534.	0.8	86

#	Article	IF	Citations
127	Regulation of dendritic cell expansion in aged athymic nude mice by FLT3 ligand. Experimental Gerontology, 2004, 39, 339-348.	2.8	11
128	Murine prostate cancer inhibits both in vivo and in vitro generation of dendritic cells from bone marrow precursors. Prostate, 2004, 59, 203-213.	2.3	20
129	Comparative analysis of dendritic cells transduced with different anti-apoptotic molecules: sensitivity to tumor-induced apoptosis. Journal of Gene Medicine, 2004, 6, 537-544.	2.8	20
130	Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood, 2004, 104, 2107-2115.	1.4	57
131	Malfunction of the Dendritic Cell System in Cancer. , 2004, , 49-65.		1
132	Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells. Journal of Neuroimmunology, 2003, 145, 55-67.	2.3	49
133	Inhibition of Dendropoiesis by Tumor Derived and Purified Prostate Specific Antigen. Journal of Urology, 2003, 170, 2026-2030.	0.4	47
134	NK Cells Mediate Flt3 Ligand-Induced Protection of Dendritic Cell Precursors In Vivo from the Inhibition by Prostate Carcinoma in the Murine Bone Marrow Metastasis Model. Journal of Immunotherapy, 2003, 26, 468-472.	2.4	11
135	Preparation of Human Dendritic Cells for Tumor Vaccination. , 2003, 215, 437-462.		8
136	Local administration of ILâ€12â€“transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. Journal of Experimental Therapeutics and Oncology, 2002, 2, 337-349.	0.5	47
137	Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. International Journal of Cancer, 2002, 101, 61-68.	5.1	77
138	Tumor-induced dendritic cell dysfunction. , 2002, , 112-138.		5
139	H1(0) histone and differentiation of dendritic cells. A molecular target for tumor-derived factors. Journal of Leukocyte Biology, 2002, 72, 285-96.	3.3	38
140	Increased function and survival of IL-15-transduced human dendritic cells are mediated by up-regulation of IL-15Ralpha and Bcl-2. Journal of Leukocyte Biology, 2002, 72, 1037-45.	3.3	22
141	EFFECTS OF VITAMIN D (CALCITRIOL) ON TRANSITIONAL CELL CARCINOMA OF THE BLADDER IN VITRO AND IN VIVO. Journal of Urology, 2001, 165, 253-258.	0.4	85
142	Human Prostate Cancer Blocks the Generation of Dendritic Cells from CD34+ Hematopoietic Progenitors. European Urology, 2001, 39, 37-40.	1.9	27
143	Mechanisms of dendritic cell-induced T cell proliferation in the primary MLR assay. Immunology Letters, 2001, 78, 75-82.	2.5	41
144	Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate, 2001, 46, 68-75.	2.3	67

#	Article	IF	Citations
145	Identification of delta- and mu-type opioid receptors on human and murine dendritic cells. Journal of Neuroimmunology, 2001, 117, 68-77.	2.3	40
146	Human Small Cell Lung Carcinoma and Carcinoid Tumor Regulate Dendritic Cell Maturation and Function. Modern Pathology, 2001, 14, 40-45.	5.5	66
147	Transduction of Dendritic Cells with Bcl-xLIncreases Their Resistance to Prostate Cancer-Induced Apoptosis and Antitumor Effect in Mice. Journal of Immunology, 2000, 165, 1956-1964.	0.8	78
148	Th1/Th2 balance in cancer, transplantation and pregnancy. Seminars in Immunopathology, 1999, 21, 339-359.	4.0	180
149	Differential Regulation of Epidermal and Dermal Dendritic Cells by IL-12 and Flt3 Ligand. Journal of Investigative Dermatology, 1999, 113, 1028-1032.	0.7	19
150	CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. European Journal of Immunology, 1999, 29, 2148-2155.	2.9	47
151	Regulation of dendropoiesis in cancer. Clinical Immunology Newsletter, 1999, 19, 135-139.	0.1	13
152	The generation of human dendritic and NK cells from hemopoietic progenitors induced by interleukin-15. Journal of Leukocyte Biology, 1999, 66, 659-666.	3.3	24
153	Tumor's other immune targets: dendritic cells. Journal of Leukocyte Biology, 1999, 66, 336-344.	3.3	92
154	Th1/Th2 balance in cancer, transplantation and pregnancy. Seminars in Immunopathology, 1999, 21, 339-359.	4.0	5
155	Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. , 1998, 78, 196-201.		95
156	FLT3 Ligand Induces the Generation of Functionally Active Dendritic Cells in Mice. Cellular Immunology, 1997, 179, 174-184.	3.0	199
157	Dendritic cells presenting tumor antigen. Cancer Immunology, Immunotherapy, 1996, 43, 158-164.	4.2	110
158	FLT3-LIGAND INHIBITS TUMOR PROGRESSION IN MURINE MODEL. Journal of Immunotherapy, 1996, 19, 466.	2.4	3
159	Suppression of lymphocyte mitogenesis in different rat strains exposed to footshock during early diurnal and nocturnal time periods. Psychoneuroendocrinology, 1995, 20, 821-835.	2.7	14
160	Effect of a conditioned aversive stimulus on the immune response in three strains of rats. Psychoneuroendocrinology, 1995, 20, 837-849.	2.7	18